insitro to Acquire CombinAbleAI to Complete Its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

Summary

Share TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and oligonucleotide capabilities, unifying therapeutic design across all major drug modalities in a single AI engine SOUTH SAN FRANCISCO, Calif. – Jan. 12, 2026 – insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is expected to close in late January 2026, will complete insitro’s full stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics with precision – enabling biology to guide both modality selection and molecular design from target discovery through developability assessment. This integrated approach accelerates the generation of clinic-ready assets while reducing late-stage development risk. “Drug discovery has traditionally optimized molecules for potency before assessing developability – often discovering that highly potent candidates face manufacturing constraints,” said Philip Tagari, Chief Scientific Officer, insitro. “By integrating CombinAbleAI’s physics-informed, AI-driven design for complex biologic therapeutics with our causal biology platform, we treat potency and manufacturability as interdependent design criteria from the outset. This fundamentally changes the translation from biological insight to viable therapeutic – instead of optimizing sequentially and hoping for serendipitous alignment, we’re designing for both simultaneously.” “We are delighted to welcome the CombinAbleAI team in Israel as fellow insitrocytes, alongside our colleagues in the U.S., Poland and Malaysia,” added Daphne Koller, Ph.D., founder and CEO, insitro. “Their addition helps launch our integrated TherML platform, which is a critical part of our end-to-end industrialized AI-enabled system built for repeatable, scalable, predictable drug discovery.” TherML supports the AI-driven design and optimization of multiple therapeutic modalities within a single platform. For complex biologics, including multi-specific antibodies and T-cell engagers, the platform utilizes CombinAbleAI’s physics-informed, AI-driven optimization engine, which is pre-trained on over 100,000 molecular dynamics surrogates to predict protein structure and…